Ocular surface disease related to tisotumab vedotin-tftv

IF 1.2 Q3 OBSTETRICS & GYNECOLOGY

Gynecologic Oncology Reports Pub Date : 2025-02-01 DOI:10.1016/j.gore.2025.101676

Daniella Lent-Schochet , Shachar Tauber , Zachary Seagrave , Grace L. Paley , Asim V. Farooq

{"title":"Ocular surface disease related to tisotumab vedotin-tftv","authors":"Daniella Lent-Schochet , Shachar Tauber , Zachary Seagrave , Grace L. Paley , Asim V. Farooq","doi":"10.1016/j.gore.2025.101676","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><div>To report a series of patients who developed ocular surface disease related to tisotumab vedotin-tftv (TV), an antibody-drug conjugate (ADC) approved for the treatment of recurrent or metastatic cervical cancer.</div></div><div><h3>Methods</h3><div>This was a multicenter retrospective chart review study of patients who developed ocular surface disease related to TV between April 1st, 2022 to August 31st, 2023.</div></div><div><h3>Results</h3><div>Five patients were identified who developed ocular surface disease while on TV. All patients received a standard ocular adverse event prophylaxis regimen with each infusion per the product label, including a cool ocular compress, topical vasoconstrictor, topical steroid, and artificial tears. All five patients developed conjunctival subepithelial fibrosis. Two patients developed bilateral pseudomembranous conjunctivitis, one of whom subsequently developed conjunctival scarring. Two patients developed a bilateral culture positive conjunctivitis, which responded to topical antibiotics. One patient developed bilateral infectious keratitis and was treated with partial thickness corneal transplantation of both eyes.</div></div><div><h3>Conclusion</h3><div>TV can be associated with ocular surface disease, including conjunctival scarring and infectious keratitis. Some cases may require surgical intervention. Oncologists and ophthalmologists should be aware of the possibility of these ocular complications, especially as more ADCs are approved. Further studies are required to determine toxicity mechanisms as well as optimal prophylaxis and management strategies.</div></div>","PeriodicalId":12873,"journal":{"name":"Gynecologic Oncology Reports","volume":"57 ","pages":"Article 101676"},"PeriodicalIF":1.2000,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11773263/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Gynecologic Oncology Reports","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2352578925000013","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction

To report a series of patients who developed ocular surface disease related to tisotumab vedotin-tftv (TV), an antibody-drug conjugate (ADC) approved for the treatment of recurrent or metastatic cervical cancer.

Methods

This was a multicenter retrospective chart review study of patients who developed ocular surface disease related to TV between April 1st, 2022 to August 31st, 2023.

Results

Five patients were identified who developed ocular surface disease while on TV. All patients received a standard ocular adverse event prophylaxis regimen with each infusion per the product label, including a cool ocular compress, topical vasoconstrictor, topical steroid, and artificial tears. All five patients developed conjunctival subepithelial fibrosis. Two patients developed bilateral pseudomembranous conjunctivitis, one of whom subsequently developed conjunctival scarring. Two patients developed a bilateral culture positive conjunctivitis, which responded to topical antibiotics. One patient developed bilateral infectious keratitis and was treated with partial thickness corneal transplantation of both eyes.

Conclusion

TV can be associated with ocular surface disease, including conjunctival scarring and infectious keratitis. Some cases may require surgical intervention. Oncologists and ophthalmologists should be aware of the possibility of these ocular complications, especially as more ADCs are approved. Further studies are required to determine toxicity mechanisms as well as optimal prophylaxis and management strategies.

查看原文本刊更多论文

与组织瘤单抗维多汀-tftv相关的眼表疾病。

摘要：本研究报告了一系列与tisotumab vedotin-tftv （TV）相关的眼表疾病患者，TV是一种被批准用于治疗复发或转移性宫颈癌的抗体-药物偶联物（ADC）。方法：对2022年4月1日至2023年8月31日期间发生TV相关眼表疾病的患者进行多中心回顾性图表回顾研究。结果：5例患者在看电视时出现眼表疾病。所有患者都接受了标准的眼部不良事件预防方案，每次输液都按照产品标签进行，包括眼部冷敷、局部血管收缩剂、局部类固醇和人工泪液。5例患者均出现结膜上皮下纤维化。两名患者发展为双侧假膜性结膜炎，其中一人随后发展为结膜瘢痕。两名患者发展为双侧培养阳性结膜炎，对局部抗生素有反应。1例患者发生双侧感染性角膜炎，采用双眼部分角膜移植治疗。结论：TV可与眼表疾病相关，包括结膜瘢痕和感染性角膜炎。有些病例可能需要手术干预。肿瘤学家和眼科医生应该意识到这些眼部并发症的可能性，特别是随着越来越多的adc被批准。需要进一步研究以确定毒性机制以及最佳预防和管理策略。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic Oncology Reports OBSTETRICS & GYNECOLOGY-

CiteScore

2.00

自引率

0.00%

发文量

183

审稿时长

41 days

期刊介绍： Gynecologic Oncology Reports is an online-only, open access journal devoted to the rapid publication of narrative review articles, survey articles, case reports, case series, letters to the editor regarding previously published manuscripts and other short communications in the field of gynecologic oncology. The journal will consider papers that concern tumors of the female reproductive tract, with originality, quality, and clarity the chief criteria of acceptance.